A Phase 1 interventional study of PORT-77 and Placebo in Healthy Adult Participants, sponsored by Portal Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Portal Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
Portal Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adult participants will receive PORT 77.
Drug: PORT-77
Healthy adult participants will receive matching placebo.
Drug: Placebo
Healthy adult participants will receive PORT 77.
Healthy adult participants will receive matching placebo.
Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of PORT-77 (Part I)
Time frame: Day 8
Number of incidence and severity of AEs as a measure of safety and tolerability of PORT-77 (Part II and III)
Time frame: Day 21
Plasma concentration of a single-dose of PORT-77 (Part I)
Time frame: Day 8
Plasma concentration of the steady-state of PORT-77 (Part II and III)
Time frame: Day 21
Plasma concentration of PORT-77 by effect of a standardized high-fat/high-calorie meal (Part I)
Time frame: Day 4
Evaluate effects of single doses of PORT-77 on ECG parameters (Part I)
Time frame: Day 8
Evaluate effects of multiple doses of PORT-77 on ECG parameters (Part II and III)
Time frame: Day 21
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Dec 2025, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PORT-77
Portal Therapeutics, Inc.